Rational design of dosage compensated expression vectors for multi‐subunit biologics manufacturing
Biotechnology Progress · 03.11.2026
DOI: 10.1002/btpr.88566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 03.11.2026. Verfasst von Satish Kallappagoudar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Process Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey, USA. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Chinese hamster ovary (CHO) cells are the predominant platform for biologics production. Expression of multi‐subunit proteins within a single CHO cell requires balanced subunit expression to achieve optimal product quality and yield. Through systematic analysis of CHO expression data generated at the discovery stage using co‐transfected monocistronic vectors, we found that subunit expression balance strongly correlates with product purity across both monoclonal and bispecific antibodies. These insights enabled the rational design of multicistronic vectors for production cell line development. For bispecific antibodies containing Fab and single‐chain variable fragment (scFv) arms, scFv chains were frequently overexpressed, contributing to reduced product purity. Increasing heavy chain (HC) expression, for example through the introduction of an additional HC gene copy, improved both purity and titer across multiple programs. Likewise, optimizing the relative positioning of knob and hole HC genes within bicistronic vectors helped balance chain expression and enhance product purity in a complex IgG‐like molecule. Overall, early‐stage monocistronic expression analysis provides a framework for rational vector design of multi‐subunit biologics, enabling more efficient cell line development with the potential to accelerate preclinical timelines and reduce resource utilization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biologics Process Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
- Discovery Biologics Protein Sciences, MRL, Merck & Co., Inc., South San Francisco, California, USA.
- Discovery Analytical Research, MRL, Merck & Co., Inc., South San Francisco, California, USA.
ORCID-Profile: Satish Kallappagoudar, Fernanda Sobreira, Xiaoyan Tang, Tania Chakraborty, Shengyuan Zhao, Ren Liu
Zitieren
APA
Kallappagoudar, S., Yilmaz, S., Niu, X., Zhang, Q., Sobreira, F., Tang, X., Jeong, J., Chakraborty, T., Vincelli, G., Zhao, S., Baker, J., Fayadat-Dilman, L., Zhang, L., Hohn, M. J., & Liu, R. (2026). Rational design of dosage compensated expression vectors for multi‐subunit biologics manufacturing. Biotechnology Progress. https://doi.org/10.1002/btpr.88566
Vancouver
Kallappagoudar S, Yilmaz S, Niu X, Zhang Q, Sobreira F, Tang X, et al. Rational design of dosage compensated expression vectors for multi‐subunit biologics manufacturing. Biotechnology Progress. 2026. doi:10.1002/btpr.88566
BibTeX
@article{Kallappagoudar2026,
author = {Kallappagoudar, Satish and Yilmaz, Sultan and Niu, Xiangfeng and Zhang, Qinghao and Sobreira, Fernanda and Tang, Xiaoyan and Jeong, Johan and Chakraborty, Tania and Vincelli, Gabriele and Zhao, Shengyuan and Baker, Jeanne and Fayadat-Dilman, Laurence and Zhang, Lin and Hohn, Michael Jurgen and Liu, Ren},
title = {Rational design of dosage compensated expression vectors for multi‐subunit biologics manufacturing},
journal = {Biotechnology Progress},
year = {2026},
doi = {10.1002/btpr.88566}
}
EUVIMED